Our aim was to explore the impact of the HER2/neu, HER3 receptor as well as their ligands' neuregulin (NRG1) expression on the outcome of patients with metastatic colorectal cancer (mCRC). NRG1, HER2/neu and HER3 expression was evaluated in 208 patients with mCRC receiving 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as the first-line treatment. Biomarker expression was correlated with the outcome of patients. 
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Introduction
Treatment of metastatic colorectal cancer (mCRC) has improved since molecular biomarkers are being evaluated for their predictive and prognostic information, such as RAS mutations for epidermal growth factor receptor (EGFR)-targeted treatment [1, 2] . Together with the HER2/neu, HER3 and HER4 receptor, the EGFR belongs to the HER receptor family [3] . These receptors have tyrosine kinase activity. When activated, the receptors engage intracellular signalling pathways leading to proliferation [4] [5] [6] [7] [8] .
HER2/neu overexpression was identified as valuable target in subpopulations of breast cancer and gastric cancer [9] [10] [11] . The HERACLES trial has further identified HER2/neu overexpression as a targetable structure in a subset of patients with KRAS wild-type mCRC [12] . Besides this potential predictive relevance, the unfavourable outcome of colorectal cancer (CRC) patients has been associated with HER2/neu overexpression in previous analyses [13, 14] .
Potentially treatment-relevant expression of the HER3 receptor has been reported in several solid cancer types [15] . If neuregulin (NRG1) binds to the HER3 receptor, HER3 forms heterodimers with the HER2/neu receptor [6] . Subsequently, the PI3K-AKT and MAPK pathways are activated, which stimulate tumour proliferation [6, 15] . In the literature, HER3 expression rates in CRC cells range from 34 to 90% [15] . However, it is not clear if HER3 expression is associated with patients outcome in colorectal cancer. HER3 overexpression was reported to be a negative prognostic marker for patients with CRC without distant metastases [16] [17] [18] .
In addition, previous investigations focused on the role of NRG1 in CRC as being the activating ligand of the HER3 receptor. De Boeck et al. [19] found tumour progression to be highly influenced by bone marrow-derived mesenchymal stem cells releasing NRG1 in vitro and in vivo. Furthermore, two investigations indicated a potential role for predicting lymph node involvement and the occurrence of distant metastases [20] [21] [22] . Nevertheless, two cohorts of advanced CRC and one study of a cohort of CRC patients with distant metastases did not confirm effects on outcome [23] [24] [25] . Coalteration of HER2/neu and HER3 expression was found rarely, also without impact on the outcome of patients with CRC [23] .
This analysis was designed to confirm the prevalence and prognostic impact of HER2/neu, HER3 and NRG1 expression in a chemotherapy-based study cohort of 208 patients with mCRC (FIRE-1 trial) receiving either 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line therapy. To our knowledge, the FIRE-1 trial is the first randomized-controlled trial to investigate the impact of HER2/neu and HER3 receptor overexpression in relation to NRG1 expression [16] [17] [18] [20] [21] [22] [23] [24] .
Methods
Study design and treatment schedule FIRE-1 was a multicentre phase III study. The protocol, primary results and characteristics of patients have been published previously [26] . Also, details on the subpopulation evaluable for translational research have been reported [27] . Information on RAS mutation status and EGFR ligand expression was available for the cohort as described previously [27] .
Patients
Our analysis included 208 of 479 patients with available tumour material [27] for the analysis of HER2/neu, HER3 and NRG1 expression.
Ethics
The trial was conducted in accordance with the Declaration of Helsinki (1996) . All patients provided written informed consent to be treated within a clinical trial. This investigation was performed as a retrospective evaluation with the approval of the local ethics committee of the University of Munich (registry-number: 545-11).
End points
For this manuscript, overall survival (OS) (time from randomization to death), progression-free survival (PFS) (interval between randomization and death or progression) and response rate (WHO classification: complete remission, partial remission, no change, progressive disease) were used to correlate molecular characteristics with the outcome of patients of the FIRE-1 trial.
Immunohistochemistry
Immunohistochemistry was performed using 5 μm whole standard tissue sections of FFPE tumour samples. For the detection of HER2/neu, a prediluted anti-HER2/neu rabbit monoclonal antibody (clone 4B5; Ventana Medical Systems, Oro Valley, Arizona, USA) was used as the primary antibody. The staining was performed on a Ventana Benchmark XT autostainer using the XT UltraView diaminobenzidine kit (Ventana Medical Systems) following the manufacturer's protocols. Staining of HER3 and NRG1 was performed using the Vectastain ABC-Kit Elite Universal detection system (Vector Laboratories, Peterborough, UK). For HER3 immunohistochemistry, a monoclonal rabbit antibody was used as the primary antibody (ab93739; Abcam, Cambridge, UK). NRG1 staining was performed using a polyclonal human antibody (HPA010964; Atlas Antibodies, Stockholm, Sweden).
Scoring of high and low expression, FISH
As no evident and standardized method for dividing high and low expression of HER2/neu, HER3 and NRG1 existed at the time of evaluation, we used the HER2/neu score of Rüschoff and colleagues in gastric cancer for scoring complete biomarker expression. Therefore, membrane staining was graduated by intensity (0: none, 1 + : weak, 2 + : moderate, 3 + : strong) and percentage of stained tumour cells (Fig. 1) . High expression was defined by a percentage of more than 10% stained tumour cells and at least moderate (2 + or 3 + ) membrane staining versus no or weak staining (0 or 1 + ) for low expression. In addition, two-colour fluorescence in-situ hybridization (FISH) was performed in patients showing moderate (2 + ) HER2/neu staining. Chromosome 17 centromere signals (green) as well as HER2 gene signals (red) were counted in at least 20 nuclei of colorectal tumour cells. Thus, a red to green ratio of at least 2 indicated amplification of HER2. Primary tumour slides were evaluated by two independent observers (A.S. and J.N.) using a light microscope. Disagreements (< 5%) were reviewed together, followed by conclusive judgement.
Statistical analysis
OS and PFS stratified by the molecular markers were estimated using Kaplan-Meier analysis. Significant differences were evaluated using the log-rank test and Cox regression analysis. Univariate Cox regression was performed in subgroups. The correlation of clinicopathologic parameters with biomarker expression was assessed using the χ 2 -test and the Fisher exact test for nominal variables. All P-values of less than 0.05 (two sided) were considered significant. SPSS PASW 18.0 (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis.
Results

Study population
HER2/neu, HER3 and NRG1 analyses were carried out in 208 tumours. Characteristics of the entire patient population and the evaluable subpopulation have been published before [27] . According to baseline and tumour characteristics as well as PFS and OS, the subpopulation was well comparable with the entire study population [27] .
Prevalence of high NRG1, HER3 and HER2/neu expression
Of 208 metastatic colorectal tumours in total, high NRG1 expression was detected in 16 (7.7%) specimens. 139 of 208 tumours (67%) were diagnosed to have HER3 overexpression. Twenty-three (11.1%) patients showed moderate HER2/neu staining. A subsequent FISH analysis, however, showed a missing gene amplification in all of these 23 patients (HER2/neu: chromosome 17 ratio < 2.0). Therefore, only strong (3 + ) stainings in seven (3.3%) patients were accepted as high HER2/neu expression.
Correlation of NRG1, HER3 and HER2/neu
A significant correlation of biomarkers with each other could not be detected for NRG1 and HER2/neu (P = 1.00) or for NRG1 and HER3 (P = 0.41). High HER2/neu expression also did not correlate with HER3 overexpression (P = 0.43; Table 1 ).
Association of NRG1, HER3 and HER2/neu expression with RAS mutations and EGFR-ligand expression
HER3 overexpression was significantly correlated with the presence of RAS mutations (P = 0.02; Table 2 ). HER3 overexpression showed a trend towards an association 
Survival analysis
High versus low NRG1 expression significantly affected PFS (4.7 vs. 8.2 months, hazard ratio: 2.45; 95% confidence interval: 1.45-4.13; P = 0.001), but not OS (15.5 vs. 20.7 months, hazard ratio: 1.33; 95% confidence interval: 0.76-2.35; P = 0.32). HER3 and Her2/neu expression did not influence outcome (Fig 2a-d) .
Discussion
To our knowledge, the FIRE-1 trial is the first randomized-controlled trial to investigate the impact of HER2/neu and HER3 receptor overexpression in relation to NRG1 expression and RAS status in mCRC [16] [17] [18] [20] [21] [22] [23] [24] . Previous investigations focused mostly on analysing HER2/neu and HER3 expression in advanced colorectal or rectal tumours with patients receiving adjuvant radiotherapy or chemotherapy [17, 18, [20] [21] [22] . The FIRE-1 treatment schedule consisted of 5-FU/LV plus irinotecan or oxaliplatin plus irinotecan as first-line therapy, following a recommended second-line therapy with the respective crossover study regimen. With 208 patients enrolled in the analysis, our trial represents a robust investigation [16] [17] [18] [20] [21] [22] [23] [24] .
Evaluation of HER2/neu expression has been established in gastric cancer by Rüschoff et al. [9] using immunohistochemical staining and FISH in intermediate cases. Therefore, we decided to use these validated methods for patients with mCRC in accordance with the literature. HER3 expression was also evaluated by immunohistochemical stainings using a modified Rüschoff semiquantitative scoring system, as in previous investigations, defining overexpression by cytoplasmatic or membrane staining intensity [16, 18, 23, 24] . As scoring of NRG1 expression is not yet standardized for any tumour type [19] , we also used an adapted Rüschoff score.
In FIRE-1, 3.3% of tumours showed high HER2/neu expression. This compares favourably to the average expression rate of HER2/neu in the literature of ∼ 5.0% [12, 13, 23] . In FIRE-1, 67% of primary tumours showed high HER3 expression, comparing favourably to recent other cohorts (Seo et al. [23] : 69%; Lédel et al. [18, 22] : 70%). One trial evaluating transmembrane NRG1 expression in CRC reported a frequency of high expression of 76%, in contrast to 8% in FIRE-1 [19] . However, a standardized scoring system is missing in this case, which may explain the discrepancy.
We attempted to correlate expression rates of HER receptors with HER ligands (NRG1) as well as downstream molecules (RAS). Unlike a previous investigation, we could not associate HER3 expression with NRG1 expression [19] . In our investigation, regular simultaneous expression of HER2/neu and HER3 was also not detected, although coexpression of HER2/neu and HER3 has been described in cohort of 364 surgically resected CRC patients [28] . The latter discrepancy might be caused in part by the different clinical backgrounds of patients as well as by the different diagnostic methods used.
By contrast, in our cohort, HER3 expression correlated with RAS mutations, although HER3 expression could not be associated with KRAS mutations previously [21] . This observation might have resulted from a higher number of patients enrolled in our investigation in addition to an extended analysis of RAS mutations.
In our study, high NRG1 expression led to a significant decrease in PFS. This finding is supported by a previous investigation that also observed significantly worse 5-year PFS in patients with mCRC and high NRG1 expression [19] . Because of the small numbers of patients showing high NRG1 expression, conclusions are limited. The sample size of patients with HER2/neu overexpression in our cohort does not allow for conclusions on the prognostic impact. It is noteworthy that HER3 overexpression was not associated with an unfavourable outcome in FIRE-1, although conflicting data may exist [16] [17] [18] 24, 28] . However, the small number of patients enrolled in some trials limits conclusions.
Our investigation had several strengths. FIRE-1 was a randomized-controlled trial with irinotecan-based treatment, which had a rather small likelihood of bias in terms of the outcome and follow-up information. Unfortunately, although 208 patients were enrolled in this investigation, which represented a rather robust sample size, numbers in subgroups (NRG1, Her2/neu) became small. It might also be argued that treatment in FIRE-1 does not comply with the latest recommendations. In addition, FIRE-1, as well as previous investigations, lacked a validation collective for a proofof-principle analysis. Therefore, further research is warranted to evaluate prognostic effects.
Conclusion
A significant unfavourable impact on PFS was observed in patients with mCRC with a high NRG1 expression in the FIRE-1 trial. We did not detect a prognostic impact of HER2/neu and HER3 overexpression in mCRC with respect to PFS and OS.
